Hologic - HOLX Stock Forecast, Price & News

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment in the United States, Europe, the Asia-Pacific, and internationally. It operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. The company provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load tests for HIV, Hepatitis C, and Hepatitis B; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays for the detection of SARS-CoV-2; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for the detection of Group B Streptococcus. It also offers breast imaging and analytics, such as 2D and 3D digital mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, breast biopsy site markers and localization, specimen radiology, and ultrasound and connectivity solutions; and breast conserving surgery products. In addition, the company provides NovaSure Endometrial Ablation System for the treatment of abnormal uterine bleeding; MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids, polyps, and other pathology within the uterus; and Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures. Further, it offers Horizon DXA, a dual energy X-ray system; and the Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. The company sells its products through direct sales and service forces, and independent distributors and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

Analysts Set New Price Targets

A number of research firms have recently weighed in on HOLX. BTIG Research cut Hologic from a "buy" rating to a "neutral" rating in a research report on Monday, July 18th. Bank of America cut Hologic from a "buy" rating to a "neutral" rating and lowered their price objective for the company from $81.00 to $75.00 in a research report on Wednesday, July 20th. Wells Fargo & Company cut Hologic from an "overweight" rating to an "equal weight" rating and lowered their price objective for the company from $90.00 to $75.00 in a research report on Monday, April 25th. UBS Group began coverage on Hologic in a research note on Wednesday, July 20th. They set a "neutral" rating and a $73.00 target price on the stock. Finally, Citigroup decreased their target price on Hologic from $78.00 to $75.00 in a research note on Thursday, April 28th. Seven equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Hold" and an average price target of $76.71.

Hologic Stock Performance

NASDAQ:HOLX opened at $73.47 on Tuesday. The company has a debt-to-equity ratio of 0.57, a current ratio of 3.91 and a quick ratio of 3.32. Hologic has a 1 year low of $66.58 and a 1 year high of $81.04. The stock's 50 day simple moving average is $70.76 and its two-hundred day simple moving average is $72.95. The company has a market cap of $18.34 billion, a price-to-earnings ratio of 12.39, a PEG ratio of 0.83 and a beta of 1.05.

Hologic (NASDAQ:HOLX - Get Rating) last released its quarterly earnings data on Wednesday, July 27th. The medical equipment provider reported $0.95 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.69 by $0.26. Hologic had a return on equity of 37.48% and a net margin of 28.93%. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $896.71 million. During the same quarter in the previous year, the company posted $1.33 EPS. The company's revenue was down 14.2% compared to the same quarter last year. As a group, equities analysts anticipate that Hologic will post 5.82 earnings per share for the current fiscal year.